These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 17174423

  • 1. Serial NT-proBNP monitoring and outcomes in outpatients with decompensation of heart failure.
    Bayes-Genis A, Pascual-Figal D, Fabregat J, Domingo M, Planas F, Casas T, Ordoñez-Llanos J, Valdes M, Cinca J.
    Int J Cardiol; 2007 Sep 03; 120(3):338-43. PubMed ID: 17174423
    [Abstract] [Full Text] [Related]

  • 2. Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients.
    Pascual-Figal DA, Domingo M, Casas T, Gich I, Ordoñez-Llanos J, Martínez P, Cinca J, Valdés M, Januzzi JL, Bayes-Genis A.
    Eur Heart J; 2008 Apr 03; 29(8):1011-8. PubMed ID: 18263871
    [Abstract] [Full Text] [Related]

  • 3. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients.
    Bettencourt P, Azevedo A, Pimenta J, Friões F, Ferreira S, Ferreira A.
    Circulation; 2004 Oct 12; 110(15):2168-74. PubMed ID: 15451800
    [Abstract] [Full Text] [Related]

  • 4. Usefulness and predictive value of circulating NT-proBNP levels to stratify patients for referral and priority treatment in a specialized outpatient heart failure center.
    Amir O, Paz H, Ammar R, Yaniv N, Schliamser JE, Lewis BS.
    Isr Med Assoc J; 2008 Feb 12; 10(2):109-12. PubMed ID: 18432021
    [Abstract] [Full Text] [Related]

  • 5. Prognosis of decompensated heart failure patients with preserved systolic function is predicted by NT-proBNP variations during hospitalization.
    Bettencourt P, Azevedo A, Fonseca L, Araújo JP, Ferreira S, Almeida R, Rocha-Goncalves F, Ferreira A.
    Int J Cardiol; 2007 Apr 12; 117(1):75-9. PubMed ID: 16843555
    [Abstract] [Full Text] [Related]

  • 6. Cutoff values of NT-proBNP for the prediction of low functional capacity, decreased ejection fraction and cardiovascular events in patients with heart failure.
    Koç M, Bozkurt A, Yildiray-Sahin D, Unal I, Acartürk E.
    Cardiol J; 2009 Apr 12; 16(1):43-9. PubMed ID: 19130415
    [Abstract] [Full Text] [Related]

  • 7. NT-ProBNP reduction percentage during hospital stay predicts long-term mortality and readmission in heart failure patients.
    Verdiani V, Ognibene A, Rutili MS, Lombardo C, Bacci F, Terreni A, Nozzoli C.
    J Cardiovasc Med (Hagerstown); 2008 Jul 12; 9(7):694-9. PubMed ID: 18545069
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Lack of decrease in plasma N-terminal pro-brain natriuretic peptide identifies acute heart failure patients with very poor outcome.
    Kubler P, Jankowska EA, Majda J, Reczuch K, Banasiak W, Ponikowski P.
    Int J Cardiol; 2008 Oct 13; 129(3):373-8. PubMed ID: 18054808
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Value of admission NT-proBNP in predicting in-hospital mortality in decompensated systolic heart failure].
    Wei BQ, Yang YJ, Zhang J, Zhang YH, Kang LM, Dou KF, Wang D, Lü R, Gao X, Yu LT, Wang GG, Yang YM, Tan HQ, Zhu J.
    Zhonghua Yi Xue Za Zhi; 2009 Jul 28; 89(28):1955-9. PubMed ID: 19950568
    [Abstract] [Full Text] [Related]

  • 15. Quality of life and chronic heart failure therapy guided by natriuretic peptides: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study.
    Bhardwaj A, Rehman SU, Mohammed AA, Gaggin HK, Barajas L, Barajas J, Moore SA, Sullivan D, Januzzi JL.
    Am Heart J; 2012 Nov 28; 164(5):793-799.e1. PubMed ID: 23137512
    [Abstract] [Full Text] [Related]

  • 16. Effect of atrial fibrillation on plasma NT-proBNP in chronic heart failure.
    Corell P, Gustafsson F, Kistorp C, Madsen LH, Schou M, Hildebrandt P.
    Int J Cardiol; 2007 May 02; 117(3):395-402. PubMed ID: 16919342
    [Abstract] [Full Text] [Related]

  • 17. Chromogranin A and C-terminal endothelin-1 precursor fragment add independent prognostic information to amino-terminal proBNP in patients with acute destabilized heart failure.
    Dieplinger B, Gegenhuber A, Struck J, Poelz W, Langsteger W, Haltmayer M, Mueller T.
    Clin Chim Acta; 2009 Feb 02; 400(1-2):91-6. PubMed ID: 19000665
    [Abstract] [Full Text] [Related]

  • 18. Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study.
    Bhardwaj A, Rehman SU, Mohammed A, Baggish AL, Moore SA, Januzzi JL.
    Am Heart J; 2010 Apr 02; 159(4):532-538.e1. PubMed ID: 20362709
    [Abstract] [Full Text] [Related]

  • 19. Hyponatremia, natriuretic peptides, and outcomes in acutely decompensated heart failure: results from the International Collaborative of NT-proBNP Study.
    Mohammed AA, van Kimmenade RR, Richards M, Bayes-Genis A, Pinto Y, Moore SA, Januzzi JL.
    Circ Heart Fail; 2010 May 02; 3(3):354-61. PubMed ID: 20332419
    [Abstract] [Full Text] [Related]

  • 20. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
    Sanders-van Wijk S, Maeder MT, Nietlispach F, Rickli H, Estlinbaum W, Erne P, Rickenbacher P, Peter M, Pfisterer MP, Brunner-La Rocca HP, TIME-CHF Investigators.
    Circ Heart Fail; 2014 Jan 02; 7(1):131-9. PubMed ID: 24352403
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.